Drug Profile
Avadomide - Celgene Corporation
Alternative Names: CC 122Latest Information Update: 29 Jan 2024
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Developer Bristol-Myers Squibb; Celgene Corporation; H. Lee Moffitt Cancer Center and Research Institute; Juno Therapeutics
- Class Antineoplastics; Piperidones; Quinazolines
- Mechanism of Action CRBN protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Malignant melanoma
- Phase I/II Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Liver cancer; Non-Hodgkin's lymphoma
- Phase I Solid tumours
- No development reported Glioblastoma; Multiple myeloma
Most Recent Events
- 12 Dec 2023 Celgene terminates a phase I trial in Diffuse large B-cell lymphoma (Combination therapy, Second-line therapy or greater) in Canada, Italy, USA and France (PO) as the trial was replaced with another clinical trial (NCT02031419)
- 21 Nov 2023 Celgene Corporation completes a phase I trial in Glioblastoma, Non-Hodgkin's lymphoma, Multiple myeloma and Solid tumours in USA, Belgium, Italy, France and Spain (PO) (NCT01421524)
- 28 Sep 2023 Celgene Corporation plans a phase Ib trial for Diffuse large B-cell lymphoma and Non-Hodgkin's lymphoma (Second-line therapy or greater, Combination therapy) in Italy, the Netherlands and France (NCT02417285) (Eudra CT 2014-003333-26)